RBC Capital analyst Douglas Miehm maintained a Buy rating on Bausch Health Companies (NYSE:BHC) Inc on Thursday, setting a price target of $42, which is approximately 35.27% above the present share price of $31.05.
Miehm expects Bausch Health Companies Inc to post earnings per share (EPS) of $0.20 for the first quarter of 2021.
The current consensus among 10 TipRanks analysts is for a Moderate Buy rating of shares in Bausch Health Companies, with an average price target of $32.78.
The analysts price targets range from a high of $42 to a low of $22.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $2.14 billion and a net profit of $470 million. The company's market cap is $11.03 billion.
According to TipRanks.com, RBC Capital analyst Douglas Miehm is currently ranked with 2 stars on a 0-5 stars ranking scale, with an average return of 1.1% and a 44.80% success rate.
Bausch Health Companies Inc is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets.